Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

PARIS (Reuters) -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, ...

Pfizer's abnormally high yield seems more a symptom of all this negative sentiment than a red flag about the dividend's sustainability. Management just raised the quarterly dividend in December, and ...

Just hours after thousands of U.S. Food and Drug Administration employees were shown the door, Barclay Butler, the agency’s ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer (PFE) stock was up on Monday despite the pharmaceutical company ending the clinical trial of its once-daily GLP-1 weight loss pill, ...